Inhaled allergen bronchoprovocation tests.
(2013) In Journal of Allergy and Clinical Immunology 132(5). p.1045-1045- Abstract
- The allergen bronchoprovocation test is a long-standing exacerbation model of allergic asthma that can induce several clinical and pathophysiologic features of asthma in sensitized subjects. Standardized allergen challenge is primarily a research tool, and when properly conducted by qualified and experienced investigators, it is safe and highly reproducible. In combination with validated airway sampling and sensitive detection techniques, allergen challenge allows the study of several features of the physiology of mainly TH2 cell-driven asthma in relation to the kinetics of the underlying airway pathology occurring during the allergen-induced late response. Furthermore, given the small within-subject variability in allergen-induced airway... (More)
- The allergen bronchoprovocation test is a long-standing exacerbation model of allergic asthma that can induce several clinical and pathophysiologic features of asthma in sensitized subjects. Standardized allergen challenge is primarily a research tool, and when properly conducted by qualified and experienced investigators, it is safe and highly reproducible. In combination with validated airway sampling and sensitive detection techniques, allergen challenge allows the study of several features of the physiology of mainly TH2 cell-driven asthma in relation to the kinetics of the underlying airway pathology occurring during the allergen-induced late response. Furthermore, given the small within-subject variability in allergen-induced airway responses, allergen challenge offers an adequate disease model for the evaluation of new (targeted) controller therapies for asthma in a limited number of subjects. In proof-of-efficacy studies thus far, allergen challenge showed a fair positive predicted value and an excellent negative predictive value for the actual clinical efficacy of new antiasthma therapies, underscoring its important role in early drug development. In this review we provide recommendations on challenge methods, response measurements, sample size, safety, and harmonization for future applications. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4143338
- author
- Diamant, Zuzana LU ; Gauvreau, Gail M ; Cockcroft, Don W ; Boulet, Louis-Philippe ; Sterk, Peter J ; de Jongh, Frans H C ; Dahlén, Barbro and O'Byrne, Paul M
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Allergy and Clinical Immunology
- volume
- 132
- issue
- 5
- pages
- 1045 - 1045
- publisher
- Elsevier
- external identifiers
-
- wos:000326235600003
- pmid:24119772
- scopus:84887025939
- pmid:24119772
- ISSN
- 1097-6825
- DOI
- 10.1016/j.jaci.2013.08.023
- language
- English
- LU publication?
- yes
- id
- 75ba588c-953d-4d61-9e7e-e7b491bd666b (old id 4143338)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24119772?dopt=Abstract
- date added to LUP
- 2016-04-01 11:07:50
- date last changed
- 2022-04-05 00:27:39
@article{75ba588c-953d-4d61-9e7e-e7b491bd666b,
abstract = {{The allergen bronchoprovocation test is a long-standing exacerbation model of allergic asthma that can induce several clinical and pathophysiologic features of asthma in sensitized subjects. Standardized allergen challenge is primarily a research tool, and when properly conducted by qualified and experienced investigators, it is safe and highly reproducible. In combination with validated airway sampling and sensitive detection techniques, allergen challenge allows the study of several features of the physiology of mainly TH2 cell-driven asthma in relation to the kinetics of the underlying airway pathology occurring during the allergen-induced late response. Furthermore, given the small within-subject variability in allergen-induced airway responses, allergen challenge offers an adequate disease model for the evaluation of new (targeted) controller therapies for asthma in a limited number of subjects. In proof-of-efficacy studies thus far, allergen challenge showed a fair positive predicted value and an excellent negative predictive value for the actual clinical efficacy of new antiasthma therapies, underscoring its important role in early drug development. In this review we provide recommendations on challenge methods, response measurements, sample size, safety, and harmonization for future applications.}},
author = {{Diamant, Zuzana and Gauvreau, Gail M and Cockcroft, Don W and Boulet, Louis-Philippe and Sterk, Peter J and de Jongh, Frans H C and Dahlén, Barbro and O'Byrne, Paul M}},
issn = {{1097-6825}},
language = {{eng}},
number = {{5}},
pages = {{1045--1045}},
publisher = {{Elsevier}},
series = {{Journal of Allergy and Clinical Immunology}},
title = {{Inhaled allergen bronchoprovocation tests.}},
url = {{http://dx.doi.org/10.1016/j.jaci.2013.08.023}},
doi = {{10.1016/j.jaci.2013.08.023}},
volume = {{132}},
year = {{2013}},
}